Table 1. Retargeted FVs integrate farther away from proto-oncogenes and other genomic features.
| Vector | Total sites | Percent of RIS |
||||
|---|---|---|---|---|---|---|
| In RefSeq genes | <10 kb from TSS | CpG islandsa | <50 kb from proto- oncogene TSS | <500 kb from proto-oncogene TSS | ||
| ControlIMR90 | 1760 | 36.6 | 25.2 | 9.7 | 3.6 | 23.5 |
| IN-CBX1IMR90 | 3328 | 35.5 | 26.5 | 8.7 | 3.9 | 23.3 |
| Gag-RTYIMR90 | 1541 | 32.3*** | 12.1*** | 2.4*** | 1.5*** | 13.4*** |
| IN-CBX1 & Gag-RTYIMR90 | 960 | 27.5***,## | 12.3*** | 3.0*** | 1.7*** | 13.5*** |
| ControlCD34 | 4217 | 40.9 | 24.5 | 6.5 | 4.7 | 23.3* |
| IN-CBX1 & Gag-RTYCD34 | 1534 | 30.6*** | 12.5*** | 2.5*** | 2.2*** | 15.3*** |
| Random | 10000 | 49.4 | 14.5 | 2.4 | 6.8 | 44.6 |
***Statistically significant at p < 0.001 compared to control vector.
##Statistically significant at p < 0.01 compared to Gag-RTY vector.
aWithin or less than 1 kb from a CpG island. RIS, retroviral vector integration sites; TSS, transcription start site.